Stock Analysis
SyntheticMR (NGM:SYNT) Third Quarter 2023 Results
Key Financial Results
- Revenue: kr23.0m (up 12% from 3Q 2022).
- Net income: kr4.09m (flat on 3Q 2022).
- Profit margin: 18% (down from 20% in 3Q 2022). The decrease in margin was driven by higher expenses.
- EPS: kr0.10.
All figures shown in the chart above are for the trailing 12 month (TTM) period
SyntheticMR Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 17%.
Looking ahead, revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare Services industry in Sweden.
Performance of the Swedish Healthcare Services industry.
The company's shares are up 6.3% from a week ago.
Risk Analysis
You still need to take note of risks, for example - SyntheticMR has 4 warning signs (and 1 which makes us a bit uncomfortable) we think you should know about.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NGM:SYNT
SyntheticMR
Engages in the development and marketing of imaging solutions for magnetic resonance imaging (MRI) in Sweden, the Middle East, Africa, Europe, North America, South America, and the Asia-Pacific.